The Role of CYP2C9 Gene Polymorphisms on Anticoagulant Therapy after Heart Valve Replacement

Objective: The aim of the present study was to investigate the role of CYP2C9 gene polymorphisms after heart valve replacement in a group of patients on warfarin therapy. Materials and Methods: The study population consisted of 74 patients with heart valve replacement. Peripheral blood was collected into evacuated tubes containing EDTA, and DNA was extracted from circulating leukocytes by using a high pure PCR template preparation kit. CYP2C9 * 2, CYP2C9 * 3 alleles were detected by using real-time PCR. Results: The patients with CYP2C9 * 1/ * 3 and CYP2C9 * 2/ * 3 genotypes were taking 28.21 and 24.47 mg, respectively, as mean weekly warfarin dose, whereas patients with CYP2C9 * 1/ * 1 genotype were taking 33.90 mg. Conclusion: The data show that patients with CYP2C9 * 1/ * 3 and CYP2C9 * 2/ * 3 genotypes needed a lower maintenance dose of warfarin than patients with CYP2C9 * 1/ * 1 wild-type genotype